Rifaximin‐ciprofloxacin combination therapy is effective in chronic active refractory pouchitis

200593 citationsJournal Article

Authors

Ayman S. Abdelrazeq · Hull York Medical School

S. H. Leveson · Hull York Medical School

Abstract

Rifaximin-ciprofloxacin combination therapy is safe and objectively effective in chronic active refractory pouchitis and may salvage a significant percentage of 'at risk pouches'.

Topics & Keywords

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Immunodeficiency and Autoimmune Disorders Respiratory and Cough-Related Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Colorectal Disease

Volume 7, Issue 2, pp. 182-186

DOI: 10.1111/j.1463-1318.2004.00746.x

Field-Weighted Citation Impact: 2.75